SOPHiA GENETICS (SOPH) Current Deferred Revenue (2020 - 2025)

SOPHiA GENETICS has disclosed Current Deferred Revenue across 6 years of filings, most recently posting $16.7 million for Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $16.7 million, up 191.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $16.7 million (up 191.7% YoY), and the FY2025 annual result was $16.7 million, up 191.7% from the prior year.
• Current Deferred Revenue came in at $16.7 million for Q4 2025 at SOPHiA GENETICS, up from $10.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $16.7 million in Q4 2025 to a low of $3.4 million in Q4 2022.
• The 5-year median for Current Deferred Revenue is $7.7 million (2023), against an average of $7.4 million.
• Across the five-year window, Current Deferred Revenue plunged 39.63% in 2024 and soared 191.7% in 2025, its largest moves.
• SOPHiA GENETICS's Current Deferred Revenue stood at $4.1 million in 2021, then declined by 15.61% to $3.4 million in 2022, then surged by 176.47% to $9.5 million in 2023, then slumped by 39.63% to $5.7 million in 2024, then surged by 191.7% to $16.7 million in 2025.
• The last three Current Deferred Revenue figures came in at $16.7 million (Q4 2025), $10.0 million (Q3 2025), and $9.6 million (Q2 2025), per Business Quant data.